Value, Affordability, and Decision Making - OHE

We found for

Delivering the Triple Win: A Value-Based Approach to Pricing

Italy_Balloon_AdobeStock_177931475_landscape

Insight
April 2023

Around The World in HTAs: Italy – What’s Next?

Past Event
Seminar
April 2023

Cell & Gene Therapies: Can We Find Innovative Ways to Pay?

Past Event
OHE Webinar
April 2023

Valuing Vaccines: The Economics of Vaccines & Immunisations

Informal Carer Burden Series: OHE on behalf of Roche

Insight
April 2023

Caring about Carers: Improving Consideration of the Burden of Informal Caring in HTA

Insight
March 2023

Around The World in HTAs: Spain – Are We There Yet?

Insight
February 2023

Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?

Fishing on the lake at sunset. Fishing background.

Insight
February 2023

Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges

Insight
January 2023

Combination Therapies: A Step Forward to the Value Attribution Problem

Insight
December 2022

G7 Investments in New Antibiotics Would Pay Off – For Everyone

jacek-dylag-IiQXLbTTQCw-unsplash-scaled-1

Insight
December 2022

ISPOR Europe Round-up: “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA Methodologies Appropriately Value and Enable Access?”

Insight
November 2022

The World Needs New Antibiotics. A Proposed US Program to Develop Them Offers a High Pay-Off

Insight
October 2022

The Economics of Antibiotics – Part 2: Value Assessment within the NICE-NHS AMR Pilot

Insight
June 2022

The Benefits of Early Engagement with Payers and Patient Representatives: The Case Study of a MoCA Pilot Project on ANCA-associated Vasculitis

Insight
June 2022

The State of Play for Cost-effectiveness Thresholds

Gene therapy DNA 3D chemical molecule structure low poly. Polygonal triangle point line healthy cell part. Innovation medicine genome engineering vector illustration future business technology

Insight
June 2022

ISPOR Issue Panel Roundup: Are Our HTA Methods Fit for Purpose for Gene Therapies?

Latest Research & Publications

All Publications

We found for

Filter results by

Delivering the Triple Win: A Value-Based Approach to Pricing

Around The World in HTAs: Italy – What’s Next?

Cell & Gene Therapies: Can We Find Innovative Ways to Pay?

Valuing Vaccines: The Economics of Vaccines & Immunisations

Caring about Carers: Improving Consideration of the Burden of Informal Caring in HTA

Around The World in HTAs: Spain – Are We There Yet?

Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?

Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges

Combination Therapies: A Step Forward to the Value Attribution Problem

G7 Investments in New Antibiotics Would Pay Off – For Everyone

ISPOR Europe Round-up: “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA Methodologies Appropriately Value and Enable Access?”

The World Needs New Antibiotics. A Proposed US Program to Develop Them Offers a High Pay-Off

The Economics of Antibiotics – Part 2: Value Assessment within the NICE-NHS AMR Pilot

The Benefits of Early Engagement with Payers and Patient Representatives: The Case Study of a MoCA Pilot Project on ANCA-associated Vasculitis

The State of Play for Cost-effectiveness Thresholds

ISPOR Issue Panel Roundup: Are Our HTA Methods Fit for Purpose for Gene Therapies?